Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous

Young-Youp Koh, Hyung Ho Kim, Dong-Hyun Choi1

  • 1College of Medicine, Chosun University, 375 Seo-suk dong, Dong-Gu, Gwangju 501-759, Republic of Korea. dhchoi@chosun.ac.kr.

Insights

Increasing mean platelet volume (MPV) over time is linked to clopidogrel resistance after percutaneous coronary intervention (PCI). A positive change in MPV (ΔMPV) independently predicts resistance, aiding in patient risk stratification.

Area of Science:

  • Cardiology
  • Hematology
  • Interventional Cardiology

Background:

  • Platelet reactivity is crucial in patients undergoing percutaneous coronary intervention (PCI).
  • Aspirin and clopidogrel are standard antiplatelet therapies post-PCI.
  • Assessing antiplatelet resistance is vital for optimizing patient outcomes.

Purpose of the Study:

  • To investigate the association between changes in mean platelet volume (MPV) and resistance to aspirin and clopidogrel.
  • To determine if MPV changes can predict antiplatelet resistance in PCI patients.

Main Methods:

  • Analysis of MPV and platelet function in 302 patients undergoing PCI.
  • Correlation analysis between MPV changes (ΔMPV) and platelet reactivity units (ARU, PRU, PI%).
  • Receiver operating characteristic (ROC) curve analysis to identify ΔMPV cut-off for resistance prediction.

Main Results:

  • MPV changes correlated with aspirin reaction units (ARU), P2Y12 reaction units (PRU), and P2Y12% inhibition (PI%).
  • Increasing MPV values were associated with higher PRU and lower PI% (clopidogrel resistance).
  • A positive ΔMPV (≥0.20 fL) was an independent predictor of clopidogrel resistance (OR 4.10) after PCI.

Conclusions:

  • Changes in MPV are significantly associated with platelet reactivity in PCI patients.
  • A positive ΔMPV is an independent predictive marker for clopidogrel resistance.
  • Monitoring MPV changes may help identify patients at risk for antiplatelet resistance post-PCI.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.0K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
641